Chengdu, China，December 3rd, 2018 -HitGen Ltd today announced that it has entered into a drug discovery research collaboration withGenentech, a member of the Roche Group,to identify potential small molecule leads against targets of interest to Genentech. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments fromGenentech.
“We are delighted to enter this collaboration withGenentech,an industry leader in small molecule research and development. We believe the collaboration reinforcesthe role of HitGen’s platform in the rapidly developing field of DNA-encoded chemistry. We will work closely withGenentechscientists to generate new lead compounds for their research programs to help bring transformative medicines to patients,” said Dr. Jin Li, Chairman and CEO of HitGen.
About HitGen Ltd
HitGen isa rapidly growing biotechcompanywith headquarters and custom-built research facilitiesbased in Chengdu, China,with a subsidiary in USA. HitGen has established an industry-leading platform for early-stage drug discovery researchcentred onDNA encodedchemicallibraries(DELs).HitGen’sDELsinclude encoded syntheses for more than 300billion novel, diverse, drug-likesmall molecule and macrocyclecompounds. These compounds are members of DELssynthesised frommany hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads againstbiological targets fromknown and novel classes.HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes to discover and develop the novel therapeutics of the future.
For further information, please contact
Dr. Jin Li, Chairman & CEO,HitGen Ltd. Tel: +86 28 85197385
Dr. Barry Morgan, Chief Scientific Officer, HitGen Ltd. Tel: +1 508 840 9646